Drug Pricing: Page 2
-
Win McNamee via Getty Images
Oz hints at impending CMS rule to force drug price transparency
The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug cost information, Oz said.
By Rebecca Pifer Parduhn • June 24, 2025 -
Scott Olson via Getty Images
Obesity drugsGLP-1 prescriptions for weight loss soar, despite obstacles
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, according to a new report.
By Rebecca Pifer Parduhn • May 28, 2025 -
Explore the Trendline➔
Elizabeth Regan/BioPharma Dive
TrendlineDrug pricing
President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.
By BioPharma Dive staff -
Kevin Dietsch via Getty Images
House passes reconciliation bill with massive Medicaid cuts
Speaker Mike Johnson negotiated a number of last minute changes to the megabill to get it across the finish line, including moving up the start date for Medicaid work requirements.
By Rebecca Pifer Parduhn • May 22, 2025 -
Permission granted by PHIL
Sponsored by PHILBridging the data gaps that impact retail and specialty-lite success
Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.
May 19, 2025 -
Anna Moneymaker via Getty Images
Stopping a ‘moral obscenity’: Senate Judiciary Committee expresses support for PBM reform
Sen. Chuck Grassley, R-Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass President Donald Trump’s conservative megabill this summer.
By Rebecca Pifer Parduhn • May 15, 2025 -
Andrew Harnik via Getty Images
Trump administration5 questions on Trump’s plan to lower US drug prices
The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the details on how that will happen are unclear.
By Jonathan Gardner • May 13, 2025 -
Andrew Harnik via Getty Images
Trump revives ‘most favored nation’ plan in effort to cut US drug prices
The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of discussions with substantial ramifications for drugmakers. It’s likely to be challenged in court, however.
By Jonathan Gardner , Ned Pagliarulo • Updated May 12, 2025 -
Kevin Dietsch via Getty Images
Trump administrationTrump signals plan to address ‘pill penalty’ of drug pricing law
The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the industry.
By Kristin Jensen • April 16, 2025 -
Scott Olson via Getty Images
Obesity drugs
Drug compounders sue FDA over declaration ending Wegovy shortage
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” but in earnings Monday still forecast higher revenue and profits in 2025.
By Jonathan Gardner • Feb. 25, 2025 -
Anna Moneymaker / Staff via Getty Images
Trump administrationTrump administration affirms drug price talks, but will seek input to ‘improve’ program
Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short CMS statement didn’t clear things up.
By Jonathan Gardner • Updated Jan. 30, 2025 -
Justin Sullivan via Getty Images
Judge halts Trump freeze on grants as states report healthcare payment portals back online
States and providers regained access to a key healthcare payments portal late Tuesday amid pushback over the Trump administration’s decision to halt federal assistance.
By Rebecca Pifer Parduhn • Jan. 29, 2025 -
Mario Tama / Staff via Getty Images
J&J joins Pfizer in detailing impact of Part D redesign
The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.
By Ned Pagliarulo • Jan. 22, 2025 -
Mario Tama / Getty via Getty Images
Obesity drugsMedicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
By Jonathan Gardner • Jan. 17, 2025 -
Getty Images
Ozempic, Ibrance among next drugs picked by Medicare for price talks
Announcement of the 15 medicines chosen for the second round of negotiations was one of the Biden administration’s final health policy acts.
By Ned Pagliarulo • Updated Jan. 17, 2025 -
Getty Images
FTC again goes after PBMs’ business practices in new report
Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen as the agency’s first report, but draws on more data.
By Rebecca Pifer Parduhn • Updated Jan. 14, 2025 -
Getty Images
As election day nears, Trump and Harris veer in different directions on pharma
Harris aims to broaden some IRA provisions, including Medicare drug price negotiation, while Trump has adopted a more industry-friendly approach.
By Amy Baxter • Oct. 15, 2024 -
Chip Somodevilla via Getty Images
UnitedHealth, CVS push to remove FTC Chair Lina Khan from PBM case
Attorneys argue Khan and two other commissioners are biased against pharmacy benefit managers and should recuse themselves from an ongoing lawsuit against the middlemen.
By Emily Olsen • Oct. 10, 2024 -
Scott Olson via Getty Images
Medicare tweaks rules for second round of drug price talks
The agency will offer earlier meetings with drugmakers as well as solicit more patient feedback on the process.
By Ned Pagliarulo • Oct. 3, 2024 -
Getty Images
Blue Shield of California sidesteps PBMs with new Humira biosimilar deal
It’s the first time, according to the insurer, that this type of model has been used to bring a Humira biosimilar to market, and it yields a much lower cost than both the brand-name version of the drug and biologic copycats.
By Rebecca Pifer Parduhn • Oct. 2, 2024 -
Chip Somodevilla via Getty Images
Novo CEO pressed by Senate to cut prices of obesity, diabetes drugs
CEO Lars Fruergaard Jørgensen told lawmakers the company would consider new talks with insurers about the list prices of Wegovy and Ozempic if they pledge to keep the medicines on their formularies.
By Jonathan Gardner • Sept. 24, 2024 -
Getty Images
FTC sues major pharmacy benefit managers over insulin prices
The agency brought action against Caremark, Express Scripts and Optum Rx Friday, and warned that all drug manufacturers “should be on notice” as well.
By Rebecca Pifer Parduhn • Updated Sept. 20, 2024 -
Scott Olson via Getty Images
Covering Wegovy for heart risk could cost Medicare tens of billions: study
If all newly eligible patients received Novo's GLP-1 drug, Medicare Part D spending could increase by $34 billion to $145 billion each year, according to new research.
By Emily Olsen • Aug. 27, 2024 -
Courtesy of Eisai
UK approves Leqembi, but reimbursement may not follow
Leqembi’s benefits are “too small to justify the significant cost to the NHS,” said the head of a UK agency in charge of determining medicine reimbursement.
By Kristin Jensen • Aug. 22, 2024 -
Mario Tama via Getty Images
Employers foresee higher health costs next year due to rising pharmacy spend
Pharmaceuticals like the in-demand GLP-1 drugs for obesity are expected to drive increases in healthcare spending in 2025, per a new employer survey.
By Rebecca Pifer Parduhn • Updated Aug. 21, 2024 -
Alex Wong via Getty Images
Medicare drug price cuts could have limited early impact, but grow with time
Some in the industry described the level of price discounts announced by Medicare as a "relief," though they warned of larger implications for drug research in the future.
By Jonathan Gardner • Aug. 16, 2024
Previous
